Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 07'th Nov 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
02:47pm, Tuesday, 05'th Nov 2024
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
BMRN vs. INCY: Which Stock Is the Better Value Option?
12:46pm, Monday, 04'th Nov 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is th
Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
07:41am, Thursday, 31'st Oct 2024
Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. New product approvals, like Niktimvo, should diversify Incyte's revenue and reduce r
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
04:37pm, Wednesday, 30'th Oct 2024
On Tuesday, Incyte Corporation INCY reported third-quarter revenue of $1.14 billion, up 24% year over year, beating the consensus of $1.08 billion.
Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript
01:30pm, Tuesday, 29'th Oct 2024
Incyte Corporation (NASDAQ:INCY ) Q3 2024 Results Conference Call October 29, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Exec
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
12:07pm, Tuesday, 29'th Oct 2024
On Tuesday, Incyte Corporation INCY reported third-quarter revenue of $1.14 billion, up 24% year over year and beating the consensus of $1.08 billion.
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
11:51am, Tuesday, 29'th Oct 2024
Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.
Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings
10:35am, Tuesday, 29'th Oct 2024
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Incyte raises 2024 sales forecast for top-selling drug Jakafi
09:22am, Tuesday, 29'th Oct 2024
Incyte beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong.
Incyte (INCY) Q3 Earnings Miss Estimates
09:16am, Tuesday, 29'th Oct 2024
Incyte (INCY) came out with quarterly earnings of $1.07 per share, missing the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.10 per share a year ago.
Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List
02:03pm, Thursday, 24'th Oct 2024
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SCTopEmployers--Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List.
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
03:10pm, Tuesday, 22'nd Oct 2024
INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program.
GMAB or INCY: Which Is the Better Value Stock Right Now?
12:48pm, Tuesday, 08'th Oct 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Incyte (INCY). But which of these two stocks presents inve
